Platelet and Plasma Market Background

Platelet and Plasma Market

Platelet and Plasma Market Size, Share, Insights, Competitive Landscape, and Forecast 2026 to 2033

Modified Date : Oct 2026
Format :PDFWordExcel
No. of Pages : 291
Industry : Healthcare IT

Platelet and Plasma Market Size and Trend Analysis

How Fast Will Platelet and Plasma Supply Grow Through 2033?

The global Platelet and Plasma market size is expected to be valued at US$ 18.6 billion in 2026 and projected to reach US$ 29.9 billion by 2033, growing at a CAGR of 7.02% between 2026 and 2033.

Between 2020 and 2025 the blood component supply chain expanded at an estimated 6.2% CAGR, after donor attendance fell sharply in 2020 and then recovered. Three factors carry the forecast. Demand for plasma-derived therapies, especially immunoglobulins used in primary and secondary immunodeficiency, keeps pulling fractionators to buy more litres of source plasma. Collection centre networks in the United States have been enlarged to meet that pull. Pathogen reduction and extended-storage processing raise the value of each platelet unit released, even where transfusion volumes are flat. The direction is steady volume growth, constrained less by clinical demand than by how many eligible donors can be recruited and retained.

Key Report Takeaways

  • By Product Type: Source Plasma for Fractionation held 59.0% share in 2026, while Platelet Concentrates are projected to expand at a 7.6% CAGR through 2033, as pathogen-reduced apheresis units replace lower-value pooled buffy-coat preparations.
  • By Collection Method: Apheresis Collection held 74.0% share in 2026, while Hybrid and Automated Multicomponent Collection is projected to expand at a 9.6% CAGR through 2033, because one automated session can yield plasma and two platelet doses together.
  • By Processing Technology: Conventional Processing and Leukoreduction held 61.0% share in 2026, while Pathogen Reduction Technology is projected to expand at an 11.2% CAGR through 2033, following national adoption decisions in several European blood establishments.
  • By End User: Plasma Fractionation Companies held 54.5% share in 2026, while Research and Diagnostic Laboratories are projected to expand at a 9.4% CAGR through 2033, driven by demand for human plasma reagents, control sera and cell-culture supplements.
  • By Region: North America held 44.0% share in 2026, while Asia Pacific is projected to expand at an 8.9% CAGR through 2033, supported by new plasma collection programmes in China, India and Japan.

Global Platelet and Plasma Market Trends and Insights

Drivers Impact Analysis

Two forces account for most of the forecast expansion in platelet and plasma supply.

Driver Impact on CAGR Forecast Geographic Relevance Impact Timeline
Rising immunoglobulin consumption pulling fractionators toward more source plasma litres High North America, Europe, Asia Pacific Long term (≥4 years)
Regulatory and clinical adoption of pathogen reduction raising value per platelet unit Medium Europe, North America Medium term (2–4 years)

Immunoglobulin Demand Pulls More Source Plasma Litres Into the Collection Network

Growth in plasma-derived therapy use is the single largest engine behind collection volumes. Immunoglobulin products treat primary immunodeficiencies and are also used in several immune-mediated neurological conditions, and diagnosed patient numbers have risen as awareness and testing improved. Because immunoglobulin yield per litre is finite, every additional treated patient translates directly into additional litres that fractionators must buy. That demand reaches the market as long-term supply contracts with collection centre operators.

The mechanism is a fixed biological conversion rate between donation and therapy. A fractionation plant cannot raise output without raising feedstock, so capacity planning starts with litres rather than with plant throughput. Albumin demand in China and clotting factor demand outside high-income markets add further pull. WHO guidance on blood availability and self-sufficiency has pushed national authorities to measure plasma supply against domestic need, which has made collection capacity a planning target rather than a by-product of whole blood donation.

Pathogen Reduction Adoption Raises the Realised Value of Each Platelet Dose

Pathogen reduction is changing platelet economics more than platelet volumes. Where a blood establishment adopts the technology, every treated dose carries an added disposable kit and illumination step, which raises the price charged to hospitals. Several European national services now treat all or most of their platelet supply this way, and uptake in North America has grown alongside bacterial risk control expectations. The result is value growth in a component whose transfusion volume is broadly stable.

The driver behind adoption is residual transfusion-transmitted infection risk and bacterial contamination of room-temperature platelets. The US Food and Drug Administration has set out bacterial risk control strategies for platelets that blood collectors must follow, and treated platelets are one accepted route to compliance. Treatment also allows some establishments to extend platelet shelf life, which reduces outdating. AABB standards for blood banks and transfusion services give hospitals a common reference for validating these processes.

Restraints Impact Analysis

Two structural limits temper the growth outlook for blood component supply.

Restraint Impact on CAGR Forecast Geographic Relevance Impact Timeline
Donor dependence and the geographic imbalance in source plasma collection High Europe, Asia Pacific, Latin America Long term (≥4 years)
Compliance cost of donor screening, testing and cold chain for short-dated components Medium Global Medium term (2–4 years)

Donor Supply Imbalance Limits How Fast Plasma Volumes Can Be Increased

Supply is bounded by donors, not by processing capacity. A large majority of the world’s source plasma is collected in the United States, where frequent donation with compensation for time is permitted. Most European member states, and many countries elsewhere, operate voluntary non-remunerated donation with lower permitted donation frequency, so their collection per head is far smaller. National systems that cannot raise domestic litres remain dependent on imported feedstock, which exposes them to any disruption at a small number of collection networks.

The underlying cause is regulatory and cultural rather than technical. Donor compensation rules differ by member state across the European Union, and Regulation (EU) 2024/1938 preserves national discretion over what compensation is allowed. Donor eligibility criteria, deferral periods, haemoglobin and protein thresholds, and inter-donation intervals all cap the yield of an existing donor base. Recruiting new donors is slow and sensitive to local demographics.

Screening, Testing and Cold Chain Compliance Costs Compress Blood Centre Margins

Compliance costs absorb much of the price that blood establishments can charge. Every donation must be screened, tested, labelled, traced and stored under controlled conditions, and platelets add agitation and strict temperature control within a short shelf life. Outdating of unused platelet units is a direct loss, and the cost of discarded components falls on the collector rather than on the hospital. Many non-profit blood centres therefore operate on thin surpluses.

The specific cost sources are identifiable. Nucleic acid amplification testing and serological screening for transfusion-transmitted infections are performed per donation, with no volume relief. FDA regulations at 21 CFR Part 606 and 21 CFR Part 640 set manufacturing practice and component standards requiring validated equipment, qualified staff and documented quality systems. Apheresis collection consumes a single-use disposable set per session. Transport fleets, validated shippers and backup power complete a fixed cost base.

Market Opportunities

Domestic Plasma Collection Programmes Outside the United States Open a New Feedstock Pool

National plasma self-sufficiency programmes represent the clearest untapped revenue pool. Several governments have concluded that dependence on imported feedstock is a strategic risk, and have begun authorising new plasmapheresis centres, revising donation frequency rules or contracting operators to build networks. Each new centre adds recurring litres under long contracts, which is attractive revenue because it is volume-based and predictable rather than tied to a product launch.

Collection centre operators, national blood establishments and fractionators with contract manufacturing arrangements are positioned to capture this. The customer is usually a health ministry or national blood authority seeking secure supply of immunoglobulin and albumin for its own population. Regulation (EU) 2024/1938, which replaces Directive 2002/98/EC, strengthens supply continuity and crisis preparedness duties for member states, giving these programmes a legal anchor. Centre siting, donor retention and apheresis device availability determine how quickly litres actually arrive.

Cold-Stored and Extended Shelf-Life Platelets Create a Trauma and Rural Supply Segment

Cold-stored platelets open a revenue pool that room-temperature products cannot serve. Conventional platelet concentrates are held at 20 °C to 24 °C with agitation and expire within days, which makes them impractical for small hospitals, remote sites and pre-hospital care. Refrigerated platelets have a longer usable life and are of growing interest for actively bleeding patients, creating demand from settings that previously stocked none at all.

Trauma centres, military medical services and rural hospital networks are the natural customers, and blood establishments that can validate the process capture the supply contract. Supporting developments include FDA-recognised storage variations for cold-stored platelets and accumulating clinical experience in massive transfusion protocols. The segment remains small and its clinical positioning is still being defined through trials, so suppliers should treat it as an adjacent product line rather than a replacement for standard platelet inventory.

Segment Analysis

By Product Type: Source Plasma for Fractionation Leads While Platelet Concentrates Gain Value

Source Plasma for Fractionation held 59.0% of 2026 revenue. It leads because fractionators buy very large, contracted volumes of apheresis plasma to feed immunoglobulin and albumin production, and because a single donor can contribute far more plasma per year than whole blood. The United States supplies the majority of these litres through a dense commercial collection network.

Platelet Concentrates are the fastest-growing product type at a 7.6% CAGR to 2033. Growth is driven by value rather than volume, as single-donor apheresis units and pathogen-reduced doses replace pooled buffy-coat preparations and carry higher release prices.

Fresh Frozen Plasma and Plasma for Transfusion, together with Cryoprecipitate and Other Plasma Components, make up the balance and track surgical and obstetric activity. The implication for suppliers is that margin improvement now depends on component mix and processing technology, not simply on collecting more units.

By Collection Method: Apheresis Dominates While Multicomponent Sessions Expand Fastest

Apheresis Collection held 74.0% share in 2026 and is the backbone of modern plasma supply. Automated separation returns red cells to the donor, which allows far higher plasma volumes per session and more frequent donation than whole blood collection permits. It also yields a single-donor platelet dose that reduces recipient exposure compared with pooling several donors.

Hybrid and Automated Multicomponent Collection is the fastest-growing method at a 9.6% CAGR. Modern separators can take a double platelet dose plus plasma in one visit, raising yield per donor hour and easing the donor recruitment constraint that limits every blood establishment.

Whole Blood Derived Collection remains important for red cell supply and for recovered plasma sent to fractionation, particularly in countries without large plasmapheresis networks. The business consequence is that device placement and disposable kit contracts increasingly determine which collector can grow capacity.

By Processing Technology: Conventional Leukoreduction Leads as Pathogen Reduction Scales

Conventional Processing and Leukoreduction accounted for 61.0% of 2026 value. Universal leukoreduction is mandated or standard practice in most high-income blood systems, is comparatively inexpensive per unit, and is embedded in existing component preparation lines, so it remains the default for the bulk of output.

Pathogen Reduction Technology is the fastest-growing processing route at an 11.2% CAGR to 2033. Adoption has moved from selective use to whole-inventory treatment in several European national services, and interest in North America has grown alongside bacterial risk control expectations for platelets.

Cold-Stored and Extended Shelf-Life Platelets and Freeze-Dried and Lyophilized Plasma are small but strategically important, because both address logistics rather than safety. For blood establishments the practical implication is a rising capital and consumable cost base per unit, which must be recovered through hospital service charges.

By End User: Fractionation Companies Buy the Most While Laboratories Grow Quickest

Plasma Fractionation Companies held 54.5% of 2026 purchases. They lead because industrial-scale plants consume continuous, contracted feedstock volumes, and because the therapies they produce command prices that support sustained investment in collection capacity upstream.

Research and Diagnostic Laboratories are the fastest-growing end user at a 9.4% CAGR. Demand comes from human plasma used as assay matrix and control material, platelet lysate as a serum substitute in cell culture, and reference reagents for diagnostics manufacturing, all of which require characterised, traceable human material.

Hospitals and Transfusion Services and Blood Banks and Blood Centers account for the remainder and set clinical specification. The implication for collectors is that a single donation stream now serves two different buyers, with very different contracting behaviour and price sensitivity.

Geography Analysis

Which Region Is Leading the Platelet and Plasma Market?

North America leads with 44.0% share of the platelet and plasma market in 2026. The United States supplies almost all of it and collects the majority of the world’s source plasma, through a large commercial plasmapheresis network concentrated in border states and population centres. Canada contributes a smaller volume and has been expanding domestic plasma collection to reduce import reliance.

Regulation explains much of the structure. FDA blood regulations at 21 CFR Part 606 and 21 CFR Part 640 set manufacturing and component standards, while AABB accreditation governs hospital transfusion practice. The move to individual donor assessment in 2023 widened the eligible donor pool without lowering screening rigour. The main change ahead is continued centre build-out and automation of donor qualification, which raises throughput per site rather than adding new sites.

Europe Balances Voluntary Donation Rules Against Plasma Import Dependence

Europe holds 25.0% of the 2026 market. Germany, Austria, Czechia and Hungary account for most plasmapheresis activity, because their national rules permit higher donation frequency and compensation for donor time, while France, Italy and Spain operate largely public, voluntary systems with lower collection per head.

The regulatory framework is being rewritten. Regulation (EU) 2024/1938 on standards of quality and safety for substances of human origin replaces Directive 2002/98/EC and the tissues and cells directives, and adds obligations on supply continuity, donor protection and registration of establishments. Member states retain discretion over donor compensation, so the collection imbalance inside the bloc is unlikely to disappear quickly. The clearest opportunity is public-private plasma centre partnerships aimed at reducing imported feedstock.

Which Region Is Growing Fastest in the Platelet and Plasma Market?

Asia Pacific is the fastest-growing geography at an 8.9% CAGR between 2026 and 2033, from 21.0% share in 2026. China drives most of that, with a large and tightly regulated domestic plasma collection station system and persistent albumin demand. Japan operates a mature, largely self-sufficient system, while India, South Korea and Australia are expanding apheresis capacity and component standards.

Two local factors shape the trajectory. Plasma collection station licensing in China is controlled provincially, so capacity growth is administrative as much as commercial. Blood safety upgrades, including wider nucleic acid testing and leukoreduction, are raising cost per unit and shifting output toward higher-specification components. The main constraint is donor recruitment in countries where voluntary donation rates per thousand population remain well below high-income norms.

Latin America Builds Capacity Around National Blood Policy Reform

Latin America represents 6.0% of the 2026 market. Brazil, Argentina, Mexico and Colombia account for most activity, with Brazil operating a large public blood network and a state-linked fractionation capability intended to convert domestic plasma into finished therapies rather than exporting feedstock.

Barriers are mainly structural. Collection is fragmented across many small hospital-based services, apheresis penetration is low outside major cities, and currency exposure makes imported disposables and test kits expensive. Voluntary donation rates vary widely between countries, and replacement donation still accounts for a meaningful share of supply in several systems. The most significant change would be regional consolidation of testing and processing into fewer, larger centres, which several national authorities have identified as a route to both quality and cost improvement.

Middle East & Africa Supply Concentrates in Gulf and North African Blood Services

Middle East & Africa accounts for 4.0% of 2026 revenue, the smallest regional share. Saudi Arabia, the United Arab Emirates, Qatar and Israel operate well-funded national blood services with apheresis platforms and modern testing, and Egypt, Morocco and South Africa run the largest programmes elsewhere in the region.

Constraints are severe beyond those clusters. Many sub-Saharan countries collect far fewer donations per thousand population than WHO considers consistent with basic transfusion need, rely heavily on family replacement donors, and lack the cold chain and testing infrastructure for routine component separation. Platelet availability is especially limited because of its short shelf life. The main opportunity is national blood service centralisation funded under health investment plans, which brings component production and quality systems into a smaller number of capable facilities.

Competitive Landscape

The platelet and plasma market is moderately concentrated, and concentration differs sharply by activity. Commercial source plasma collection is dominated by a small number of vertically integrated fractionators that operate their own centre networks to secure feedstock, which gives them scale in both collection and downstream manufacturing. Transfusion component supply, by contrast, is fragmented and largely non-commercial, delivered by national blood services, regional non-profit blood centres and hospital transfusion services. A third group supplies the technology layer: apheresis platforms, disposable kits, pathogen reduction systems, screening assays and cold chain equipment. Consolidation has been steadiest among collection centre operators, where scale lowers the cost per litre.

Competition is based on different factors in each layer. Collection operators compete on donor recruitment and retention, centre location, visit time and compliance record. Technology suppliers compete on yield per donor session, procedure time, disposable cost, validated shelf-life claims and integration with blood establishment computer systems. Blood establishments themselves compete less on price than on reliability of supply, inventory service levels and the ability to deliver specialised components such as human leucocyte antigen matched platelets. New entrants have appeared mainly as independent plasma collection networks that sell feedstock to fractionators under supply agreements.

Strategic activity centres on securing litres and lowering cost per donation. Suppliers have expanded centre footprints, invested in donor-facing digital scheduling and qualification, extended apheresis device platforms to multicomponent protocols, and pursued contract fractionation arrangements with national authorities seeking domestic supply. Technology vendors have broadened pathogen reduction into additional components and worked to align claims with national regulatory requirements.

Strategic direction is converging on three themes: feedstock security, automation of donor qualification and collection, and processing technologies that extend shelf life or reduce wastage across the component inventory.

Recent Industry Developments

  • May 2010: The World Health Assembly adopted resolution WHA63.12 on availability, safety and quality of blood products – it urged member states to build nationally coordinated, voluntary unpaid donation systems and to work toward self-sufficiency in plasma-derived medicinal products.
  • April 2020: The US Food and Drug Administration issued revised recommendations shortening several blood donor deferral periods, including the deferral for men who have sex with men from twelve months to three months – it enlarged the eligible donor pool during an acute supply shortage.
  • May 2023: The US Food and Drug Administration published final guidance introducing individual donor assessment for blood donor eligibility, replacing time-based deferrals based on sexual orientation – it changed donor screening questionnaires across every United States collection establishment.
  • June 2024: The European Parliament and the Council of the European Union adopted Regulation (EU) 2024/1938 on standards of quality and safety for substances of human origin intended for human application – it replaces Directive 2002/98/EC and the tissues and cells directives, and applies from 2027.

Companies Covered in the Report

Grifols, S.A.

CSL Limited

Takeda Pharmaceutical Company Limited

Octapharma AG

Terumo Blood and Cell Technologies

Haemonetics Corporation

Fresenius Kabi AG

Cerus Corporation

Macopharma SAS

Kedrion S.p.A.

ADMA Biologics, Inc.

Japan Blood Products Organization

Platelet and Plasma Market Report Scope

Metric Value
Study Period 2020–2033
Market Size 2026 US$ 18.6 Billion
Market Size 2033 US$ 29.9 Billion
CAGR 2026–2033 7.02%
Absolute Dollar Opportunity US$ 11.3 Billion
Largest Market North America (44.0% share in 2026)
Fastest-Growing Market Asia Pacific (8.9% CAGR 2026–2033)
Market Concentration Medium
Major Players Grifols, S.A., CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Terumo Blood and Cell Technologies

Platelet and Plasma Market Segmentation

Product Type

  • Platelet Concentrates
  • Fresh Frozen Plasma and Plasma for Transfusion
  • Source Plasma for Fractionation
  • Cryoprecipitate and Other Plasma Components

Collection Method

  • Apheresis Collection
  • Whole Blood Derived Collection
  • Hybrid and Automated Multicomponent Collection

Processing Technology

  • Conventional Processing and Leukoreduction
  • Pathogen Reduction Technology
  • Cold-Stored and Extended Shelf-Life Platelets
  • Freeze-Dried and Lyophilized Plasma

End User

  • Plasma Fractionation Companies
  • Hospitals and Transfusion Services
  • Blood Banks and Blood Centers
  • Research and Diagnostic Laboratories

Regions

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Our Research Methodology

Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.

View Methodology
Quality Assured

Quality Assured

Rigorous Validation Process

Confidentiality Assured

Confidentiality Assured

End-to-end Data Security

Custom Research Services

Custom Research Services

Tailored To Your Objectives

FAQs

The market is valued at US$ 18.6 billion in 2026, covering collection, processing, testing and distribution of platelet concentrates and human plasma worldwide.

Revenue is projected to reach US$ 29.9 billion by 2033 at a 7.02% CAGR, an absolute dollar opportunity of US$ 11.3 billion over the period.

Source Plasma for Fractionation leads with 59.0% share in 2026, because fractionators contract very large apheresis plasma volumes for immunoglobulin and albumin production.

Pathogen Reduction Technology grows fastest at an 11.2% CAGR through 2033, as European national blood services move toward treating their whole platelet inventory.

North America leads with 44.0% share in 2026, and concentration is medium, with commercial plasma collection far more consolidated than transfusion component supply.

Related Reports

Veterinary Telehealth Market Size, Share, Insights, Competitive Landscape, and Forecast 2026 to 2033

Veterinary telehealth market to grow from US$ 0.6 billion in 2026 to US$ 1.5 billion by 2033 at a 14.0% CAGR. Explore services, segments and regional insights.


Nov 2026

Chemical Peel Market Size, Share, Insights, Competitive Landscape, and Forecast 2026 to 2033

The chemical peel market is projected to grow from US$2.4 billion in 2026 to US$4.3 billion by 2033, at an 8.7% CAGR. Explore segments and regional trends.


Nov 2026

Smart Home Health Market Size, Share, Insights, Competitive Landscape, and Forecast 2026 to 2033

The smart home health market is projected to grow from US$5.80 billion in 2026 to US$9.90 billion by 2033, at a 7.9% CAGR, driven by aging and home monitoring.


Nov 2026

Population Health Management Market Size, Share, Insights, Competitive Landscape, and Forecast 2026 to 2033

The population health management market is projected to grow from US$46.93 billion in 2026 to US$132.63 billion by 2033, at a 16.0% CAGR, led by value-based care.


Nov 2026

Medical Second Opinion Market Size, Share, Insights, Competitive Landscape, and Forecast 2026 to 2033

The medical second opinion market is projected to grow from US$9.69 billion in 2026 to US$28.55 billion by 2033, at a 16.7% CAGR, led by virtual care.


Nov 2026

Patient Blood Management Market Size, Share, Insights, Competitive Landscape, and Forecast 2026 to 2033

Explore the patient blood management market, reaching US$ 25.61 billion by 2033 at 6.4% CAGR, with product and regional insights.


Nov 2026